Appeal No. 1997-3945
Application No. 08/410,390
compound so that the treated individual is not
exposed to the compound during the extended period
of protein localization at the tumor site.
According to Goodwin, the avidin-biotin interaction takes
place in vivo after the sequential administration of Goodwin's
components to a treated individual.
The immunoconjugate of claim 1 differs from the product
disclosed by Goodwin in that Goodwin's biotinylated compound
includes a pharmaceutically active toxin moiety, whereas claim
1 recites a biotinylated moiety selected from the group
consisting of cytotoxic proteins and nucleic acids, where said
protein is selected from the group consisting of gelonin,
ricin, saporin, abrin, diptheria toxin, Pseudomonas exotoxin,
rayalase, superoxide dismutase, protein tyrosine phosphatase,
protein phosphatase (PP-1 or PP-2), protein kinase A and
protein kinase C. Goodwin discloses, generically, a
pharmaceutically active toxin moiety, whereas claim 1 recites
species of cytotoxic proteins.
Pastan '985 discloses a method of chemically modifying
Pseudomonas exotoxin (PE) so that, after conjugating the
exotoxin to a monoclonal antibody (ab) such as the antibody to
the transferrin receptor, the PE-ab conjugate becomes a highly
-9-
Page: Previous 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next
Last modified: November 3, 2007